Adequate Immunogenicity And Low Rate of Severe Adverse Events After SARS-CoV-2 mRNA-Based Vaccination In Patients With Solid Malignancies On Active Treatment Starts To Decline 3 Months After Complete Primary Course of Vaccination
Published in 2022 by
U. Janzic,
U. Bidovec-Stojkovic,
K. Mohorcic,
L. Mrak,
N. F. Dovnik,
M. Ivanovic,
M. Ravnik,
M. Caks,
E. Skof,
J. Debeljak,
P. Korosec,
M. Rijavec 
